We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Oncolytics Biotech Inc (ONC) Com NPV

Sell:2.13 CAD Buy:2.15 CAD Change: 0.07 CAD (3.37%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Sell:2.13 CAD
Buy:2.15 CAD
Change: 0.07 CAD (3.37%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Sell:2.13 CAD
Buy:2.15 CAD
Change: 0.07 CAD (3.37%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oncolytics Biotech Inc. is a biotechnology company, which is engaged in developing pelareorep, an intravenously delivered immunotherapeutic agent. The Company is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

Contact details

1167 Kensington Cres Nw Suite 210
Calgary Alberta Canada T2n 1X7
T2R 0C5
+1 (403) 6707380

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
114.35 million CAD
Shares in issue:
54.98 million
Toronto Stock Exchange
Canadian dollars

Key personnel

  • Matthew Coffey
    President, Chief Executive Officer, Director
  • Kirk Look
    Chief Financial Officer
  • Andrew Guttadauro
    Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.
  • Allison Hagerman
    Vice President - Product Development
  • Thomas Heineman
    Global Head of Clinical Development and Operations of Oncolytics Biotech

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.